SWOG Cancer Research Network

Friday's SWOG Cancer Research Network Front Line post shares additional detail about our newest VA Storefront Award: More Trials for More Veterans at More VAs in More Communities #SWOGonc https://lnkd.in/gkAgGMyv

The SWOG Latin America Initiative Innovative Research on Cancer course is underway, in partnership with Peru's Instituto Nacional de Enfermedades Neoplásicas INEN. The 3-day course trains health and research professionals in cutting-edge approaches to conducting cancer clinical and translational research. A truly bilingual event, with simultaneous translation. SWOG is grateful for the commitment of INEN and the hard work of those at? Cancer Research And Biostatistics (CRAB),?and we're excited to have?American Society of Clinical Oncology (ASCO)'s CMO Dr. Julie Gralow contributing to the course's success! This photo from the opening session features? Dr. Tatiana Vidaurre, executive director of INEN's Department of Medical Oncology and site PI for INEN's SWOG membership; Dr. Charles D. Blanke, SWOG group chair; Dr. Francisco Berrospi Espinoza, INEN institutional director;? and? Dr. Adela Heredia Zelaya, INEN institutional deputy director.

Congratulations to the NORTH FLORIDA/SOUTH GEORGIA VETERANS HEALTH SYSTEM and thank you to The The Hope Foundation for Cancer Research for your continued support of VA medical centers!

Lung-MAP 3.0: The Next Generation In The Front Line, SWOG Group Chair Dr. Charles Blanke discusses a major revision of the?Lung-MAP master protocol, one that greatly expands the options for next-generation sequencing testing that can be used for matching patients to the trial's sub-studies in non-small cell #lungcancer. https://lnkd.in/edtkaFrK

The myeloMATCH precision medicine trial is building a portfolio of substudies to treat patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) sequentially from diagnosis through all stages of their treatment journey. Patients with newly diagnosed AML or MDS are screened, at no cost to them, and assigned to a treatment substudy based on clinical, cytogenetic, and molecular features. The trial’s goal is substudy assignment within about 72 hours?for newly diagnosed patients, so they can start treatment right away.? After each trial treatment, myeloMATCH reassesses the patient for assignment to a substudy in another tier or treatment stage, based on disease burden. For patients without a matching substudy, myeloMATCH follows them on their standard-of-care treatment, rescreening them later for possible future substudy assignment. myeloMATCH represents the core National Cancer Institute (NCI) clinical trial strategy for myeloid malignancies and is built on an unprecedented level of pan-NCTN collaboration. It links clinical trials in AML and MDS across the NCTN groups and NCI Division of Cancer Treatment and Diagnosis. Learn more:?https://lnkd.in/gsAN92C9

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma With a median follow-up of 2.1 years, adolescent and adult patients with stage 3 or 4 classic Hodgkin lymphoma who received initial treatment with nivolumab plus AVD chemotherapy had roughly one-half the risk of progression or death of those patients treated with a standard combination of brentuximab vedotin plus AVD. Results of S1826 just published in the @New England Journal of Medicine. Unprecedented collaboration of SWOG Cancer Research Network with Children's Oncology Group and the other groups in the National Cancer Institute (NCI)'s National Clinical Trials Network (NCTN). Congratulations to Drs. Alex Herrera, Jonathan Friedberg, Michael LeBlanc, Sharon Castellino, Kara M. Kelly, and many other pediatric & adult lymphoma investigators. S1826 is the largest classic Hodgkin lymphoma study ever conducted in the NCTN. Read the article: https://lnkd.in/gcMfCrmj Read our press release: https://lnkd.in/grsvMZfp

Today is the first day of the SWOG Fall 2024 Group Meeting in Chicago! Sessions today include our patient advocate committee and digital engagement committee sessions, a Take Action symposium on FDA diversity plans, our annual NCORP research base clinical trials workshop, & much more! You can virtually attend many of these sessions. Details are at at https://lnkd.in/eCsiqcMn

Three unique funding/learning opportunities are still open for SWOG Cancer Research Network members in this year's program cycle. You can: - Nominate a speaker for the Meyskens Prevention Lecture - Apply to our new APP mentorship program - Submit a proposal for $50K in #SEED grant funding #SWOGonc Access all of these and more via our 'Funding' page: https://lnkd.in/e2pZUTdy

The SWOG fall 2024 group meeting is next week, in Chicago and online! We'll have trial kickoff sessions for myeloMATCH (in AML & MDS), for S2312 in prostate cancer, and for the 3rd generation of Lung-MAP -- Lung-MAP 3.0. Our NCORP research base holds a clinical trials workshop on Wednesday, and Thursday features a symposium on circulating tumor DNA assay platforms. Friendly inter-committee competition will be nurtured throughout (have you completed your member profile?). Most open sessions will be accessible virtually. Session details and Zoom links are at https://lnkd.in/eCsiqcMn

In surgery for localized muscle-invasive bladder cancer, extended lymph node removal offers no survival benefit but does increase morbidity ??? The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher rate of grade 3-4 adverse events and an increased risk of death in the 90 days after surgery. The findings, published in the New England Journal of Medicine, should establish a standard bilateral pelvic lymphadenectomy that includes the external and internal iliac and obturator nodes as the standard of care for these patients. ??? Seth P. Lerner, MD, the Beth and Dave Swalm Chair in Urologic Oncology at Baylor College of Medicine, was principal investigator on the S1011 trial and chair’s the genitourinary cancers committee of the SWOG Cancer Research Network. ??? Read more: https://lnkd.in/eZY5_BUi #bladdercancer